Amarin Corp Plc (AMRN)

[Jt0082]

Thanks S! Really V is pushing up sales of the class and this is a big question I have for the board, what is stopping docs from prescribing generic L, even without a CVOT it is well covered and generic and people are very happy to generalise. Annoying!

Also for EPANOVA what happens when strength reads out? Amarin say two things:

1. Competition is good and it will build the class of omega 3s and build the market.

2. We have blocking IP that stops Epanova from coming to market

WHICH ONE IS IT? Can’t be both surely...